Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy

British Journal of Clinical Pharmacology

Volumn 69, Issue 5, 2010, Pages 484-497

  Nath, Christa E ^a   Shaw, Peter J ^a,g   Trotman, Judith ^b   Zeng, Lihua ^a   Duffull, Stephen B ^h   Hegarty, Gareth ^h   McLachlan, Andrew J ^b,g   Gurney, Howard ^c   Kerridge, Ian ^c   Kwan, Yiu Lam ^b   Presgrave, Peter ^d   Tiley, Campbell ^e   Joshua, Douglas ^f   Earl, John ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d WOLLONGONG HOSPITAL   (Australia)

^e GOSFORD HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Melphalan; Myeloma; Optimal dosing; Population pharmacokinetics; Transplantation

Indexed keywords

CREATININE; FAT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MELPHALAN; PARAPROTEIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; FEMALE; HEMATOCRIT; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE MYELOMA; OBSERVATIONAL STUDY; PLASMA CLEARANCE; POPULATION DYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; AREA UNDER CURVE; CREATINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELPHALAN; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; PARAPROTEINS; STATISTICS, NONPARAMETRIC; TRANSFERRIN; TRANSPLANTATION, AUTOLOGOUS;

EID: 77950679242     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03638.x     Document Type: Article

References (31)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996 335 : 91 7.
2. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Weston J, Nielsen JL, Wisloff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen H, Lamvik J, Lofvenberg E, Nesthus I, Rodjer S. Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic myeloma Study Group. Blood 2000 95 : 7 11.
3. Cornwell GG III., Pajak TF, McIntyre OR, Kochwa S, Dosik H. Influence of renal failure on myelosuppressive effects of melphalan: cancer and leukemia group B experience. Cancer Treat Rep 1982 66 : 475 481.
4. 2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br J Haematol 1996 95 : 527 530.
5. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol 1988 6 : 1768 1782.
6. Gertz MA, Lacy MQ, Dispenzieri A, Ansell A, Elliot SM, Gastineau DA, Inwards DJ, Micallef INM, Porrata LF, Tefferi A, Litzow MR. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004 34 : 1025 1031.
7. Reece PA, Hill HS, Green RM, Morris RG, Dale BM, Kotasek D, Sage RE. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol 1988 22 : 348 352.
8. Gera S, Musch E, Osterheld HK, Loos U. Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma. Cancer Chemother Pharmacol 1989 23 : 76 80.
9. Chang SY, Alberts DS, Farquhar D, Melnick LR, Walson PD, Salmon SE. Hydrolysis and protein binding of melphalan. J Pharm Sci 1978 67 : 682 684.
10. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001 114 : 822 829. (Pubitemid 32953738)
11. Kühne A, Sezer O, Heider U, Meineke I, Muhlke S, Niere W, Overbeck T, Hohloch K, Trümper L, Brockmöller J, Kaiser R. Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharmacol Ther 2008 83 : 749 757.
12. Junge W, Wilke B, Halabi A, Klein G. Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method. Clin Chim Acta 2004 344 : 137 148.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
14. Jones GRD, Imam SK. Validation of the revised MDRD formula and the original Cockroft and Gault formula for estimation of the glomerular filtration rate using Australian data. Pathology 2009 41 : 379 382.
15. Keys A, Fidanza F, Karvonen M, Kimura N, Taylor H. Indices of relative weight and obesity. J Chronic Dis 1972 25 : 329 343.
16. Mosteller RD. Simplified calculation of body surface area. N Engl J Med 1987 317 : 1098.
17. Janmahasatian S, Duffull S, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean body weight. Clin Pharmacokinet 2005 44 : 1051 1065.
18. Nath CE, Zeng L, Eslick A, Trotman J, Earl J. An isocratic UV HPLC assay for analysis of total and free melphalan concentrations in human plasma. Acta Chromatogr 2008 20 : 383 398.
19. Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 2007 64 : 151 164.
20. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996 30 : 329 332.
21. Gastonguay MR, El-Tahtawy A. Effect of NONMEM minimization status and number of replicates on bootstrap parameter distributions for population pharmacokinetic models: a case study. Clin Pharmacol Ther 2005 77 : 2, doi:10.1016/j.clpt.2004.11.010.
22. National Cancer Institute, USA. Common terminology Criteria for Adverse Events v 3.0 (CTCAE). Publish date: 12 December 2003. Available at http://ctep.cancer.gov (last accessed 31 March 2003).
23. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998 102 : 1115 1123.
24. 2 with blood stem cell support as first line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 2005 35 : 985 990.
25. Bjorntorp P. Obesity. Lancet 1997 350 : 423 426.
26. World Health Organization. Report of a WHO Consultant on Obesity: Preventing and managing the global epidemic.
27. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004 58 : 119 133.
28. Han PY, Duffull SB, Kirkpatrick CMJ, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007 82 : 505 508.
29. Grieg NH, Sweeney DJ, Rapoport SI. Melphalan concentration dependent plasma protein binding in healthy humans and rats. Eur J Clin Pharmacol 1987 32 : 179 185.
30. 14C-ring melphalan in blood. Biochem Pharmacol 1982 31 : 1615 1619.
31. Vassal G, Tranchand B, Valteau-Couanet D, Mahe C, Couanet D, Schoeppfer C, Grill J, Kalifa C, Hill C, Ardiet C, Hartmann O. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma. Bone Marrow Transplant 2001 27 : 471 477.